Dr. Reddy's Wins Brazil Approval for Generic Semaglutide Targeting $244.6 Million Market

Shares of Dr. Reddy’s Laboratories rebounded to ₹1,376.4 on Thursday after Brazil’s National Health Surveillance Agency cleared its generic semaglutide injection. The approval targets an addressable diabetes market valued at approximately $244.6 million. Buyers stepped in. The turnaround erased morning losses, keeping the stock’s year-to-date gain at 10%.

Brazil represents the world’s sixth-largest adult diabetes demographic, with 16.6 million people between the ages of 20 and 79 diagnosed with the metabolic condition. According to the regulatory filing, the clearance covers two pre-filled, multi-dose injectable pen presentations—2mg/1.5ml and 4mg/3ml—engineered for once-a-week administration. Physicians can prescribe the therapy as an adjunct to diet and exercise, either as monotherapy when metformin is clinically contraindicated or alongside existing anti-diabetic regimens.

Distribution Alliance With Aché

To crack open commercial channels, Dr. Reddy’s will market the GLP-1 drug in Brazil alongside domestic pharmaceutical partner Aché. The agreement combines Indian manufacturing scale with Aché’s established pharmacy and hospital distribution network.

"Our focus with semaglutide is to expand access to this treatment option across markets where the patient need is significant," said MV Ramana, chief executive officer of global generics at Dr. Reddy’s Laboratories. "Brazil, with its substantial burden of diabetes, is an important part of that journey." Ramana added that the regulatory win anchors the drugmaker’s broader international semaglutide portfolio.

The clearance clears the deck for Dr. Reddy’s to initiate commercial batch distribution schedules with Aché ahead of hospital and retail inventory rollout across Brazil.